Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

182
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
182
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

240
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
240
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

573
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
573
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

207
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
207
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

353
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
353
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

91
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
91

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma CXCL13 and fibrosis biomarkers in COVID-19 compared with idiopathic pulmonary fibrosis.

Scientific reports·2026
Same author

High Nasopharyngeal SARS-CoV-2 Load and Delayed Clearance in Hospitalized Patients With Blood Autoantibodies Neutralizing Type I Interferons.

The Journal of infectious diseases·2026
Same author

Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Assessing Covariate Clinical Relevance in High-Dimensional PK Analysis: A Comparison of SCM+, FFEM, and FREM Approaches.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Advances and Further Comparison of Software Tools for Fisher Information Matrix-Based Design Evaluation in Pharmacometrics.

Pharmaceutical research·2026
Same author

Levels of circulating kidney injury markers and IL-10 identify non-critically ill patients with COVID-19 at risk of death.

JCI insight·2026

Related Experiment Video

Updated: Dec 3, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.9K

New Model-Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse Sampling.

Florence Loingeville1,2,3, Julie Bertrand4, Thu Thuy Nguyen4

  • 1University of Paris, IAME INSERM, UMR 1137, 75018, Paris, France. florence.loingeville@univ-lille.fr.

The AAPS Journal
|October 30, 2020
PubMed
Summary

Model-based pharmacokinetic bioequivalence analysis using non-asymptotic standard errors (SE) improves type I error control in sparse sampling studies. Alternative SE calculations effectively manage inflated errors, with the posterior distribution method offering a balance of accuracy and speed.

Keywords:
bioequivalencenon-asymptotic standard errornonlinear mixed effects modelpharmacokineticstwo one-sided tests

More Related Videos

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

325
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

5.5K

Related Experiment Videos

Last Updated: Dec 3, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.9K
Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

325
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

5.5K

Area of Science:

  • Pharmacokinetics
  • Statistical modeling
  • Bioequivalence analysis

Background:

  • Traditional pharmacokinetic (PK) bioequivalence relies on non-compartmental analysis and two one-sided tests (TOST).
  • Model-based (MB) approaches using nonlinear mixed-effect models (NLMEM) are alternatives for sparse sampling but can inflate type I error with asymptotic standard errors (SE).

Purpose of the Study:

  • To propose and evaluate alternative methods for calculating SE in MB-TOST to control type I error rates in PK bioequivalence studies with sparse sampling.
  • To compare the performance of these novel SE calculation methods against traditional asymptotic SEs.

Main Methods:

  • Three alternative SE calculation methods were developed: Gallant's correction adaptation, Hamiltonian Monte Carlo for posterior distribution, and parametric bootstrap.
  • Simulations were conducted for parallel and crossover designs with rich and sparse sampling under various hypotheses.
  • Model-based TOST (MB-TOST) was employed to evaluate the methods.

Main Results:

  • All proposed alternative SE calculation methods successfully corrected the inflated type I error rate of MB-TOST in sparse PK study designs.
  • The approach utilizing the a posteriori distribution demonstrated the best performance, balancing controlled type I errors and computational efficiency.
  • Non-asymptotic SEs in MB-TOST provided better type I error control compared to asymptotic SEs for sparse PK bioequivalence.

Conclusions:

  • Novel non-asymptotic SE calculations effectively address type I error inflation in model-based pharmacokinetic bioequivalence with sparse sampling.
  • The posterior distribution approach via Hamiltonian Monte Carlo is recommended for its balance of statistical rigor and computational feasibility.
  • These findings support the use of model-based approaches with appropriate SE estimation for robust bioequivalence assessment in sparse PK studies.